WO2000001295A1 - Tissue modulation process for quantitative noninvasive in vivo spectroscopic analysis of tissues - Google Patents
Tissue modulation process for quantitative noninvasive in vivo spectroscopic analysis of tissues Download PDFInfo
- Publication number
- WO2000001295A1 WO2000001295A1 PCT/US1999/015217 US9915217W WO0001295A1 WO 2000001295 A1 WO2000001295 A1 WO 2000001295A1 US 9915217 W US9915217 W US 9915217W WO 0001295 A1 WO0001295 A1 WO 0001295A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- tissue
- spectra
- region
- collected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0048—Detecting, measuring or recording by applying mechanical forces or stimuli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
- G01N2021/653—Coherent methods [CARS]
- G01N2021/655—Stimulated Raman
Definitions
- the invention relates to methods for noninvasive spectroscopic examination of blood and/or other tissues. More particularly, the invention relates to methods for obtaining Raman spectroscopic features associated with both mobile and immobile tissues, including a method for determining blood volume and analyte concentration, and a method for detecting Raman spectroscopic features associated with skin.
- vibrational spectroscopy is a reliable mode of quantitative and qualitative ex vivo analysis for complex mixtures, and there are reports of in vitro applications of this method to metabolically interesting analytes (A.J. Berger et al., 1999, Multicomponent blood analysis by near infrared spectroscopy, Applied Optics 38(13):2916-2926 ; S.Y. Wang et al, 1993, Analysis of metabolites in aqueous solution by using laser Raman spectroscopy, Applied Optics 32(6):925-929; A. J.
- the invention provides methods for noninvasively measuring blood volume and analyte concentration and for obtaining spectroscopic information relating to immobile tissues, such as skin.
- the invention provides a noninvasive method of determining concentration of an analyte in blood of a subject.
- an analyte include, but are not limited to, glucose, urea, total protein, free fatty acids, monoglycerides, diglycerides, triglycerides, creatinine, exchangeable protein associated amide protons or cholesterol.
- the analyte is glucose.
- the method comprises irradiating a region of tissue, such as a fingertip, of the subject with a light source; collecting fluorescence spectra emitted by the region of tissue, the quantity of fluorescence spectra being indicative of blood volume; and collecting Raman spectra emitted by the region of tissue at a wavelength range that corresponds to the analyte, the quantity of Raman spectra being indicative of the amount of analyte.
- the method further comprises dividing the collected Raman spectra by the collected fluorescence spectra to obtain a number that is proportional to the concentration of analyte per unit blood volume.
- the fluorescence and Raman spectra are collected while the region of tissue is in a blood-replete state and collected while the region of tissue is in a blood-depleted state.
- the method further comprises determining the integral of net collected spectra, net collected spectra being a difference between spectra collected while the region of tissue is in a blood-replete state and spectra collected while the region of tissue is in a blood-depleted state.
- the integral of the net collected Raman spectra at the wavelength range corresponding to the analyte is divided by the integral of the net collected fluorescence spectra.
- the net collected Raman spectra is determined by:
- I( ⁇ ) incident light intensity at wavelength ⁇
- unp or u refers to an unpressed or blood-replete state
- pre or p refers to a pressed or blood-depleted state
- the method can further comprise enhancing the spectra collected by performing a 61-501 point adjacent averaging smoothing operation on the net collected spectra; subtracting the smoothed spectra from the net collected spectra; and performing a 3-27 point adjacent averaging smoothing operation on the result.
- the adjacent averaging smoothing operation of the first step is a 85-201 point smoothing operation, and more preferably, a 101 point smoothing operation.
- the adjacent averaging smoothing operation of the third step is preferably a 7 point smoothing operation.
- the light source emits light having a wavelength of about 785 nm to about 850 nm.
- a light source is a laser.
- the blood-depleted state can be achieved by tissue modulation, including by applying a tourniquet to the tissue, by pressing the tissue against a surface, or by applying an ultrasonic transducer to the region of tissue.
- the invention also provides a noninvasive method of determining concentration of an analyte in blood of a subject that comprises irradiating a region of tissue of the subject with a light source; collecting Raman spectra emitted by the region of tissue at a wavelength range that corresponds to the analyte, the quantity of Raman spectra being indicative of the amount of analyte; and measuring absorption of incident light by the region of tissue, the amount of absorbed light being indicative of blood volume.
- the method further comprises dividing the collected Raman spectra by the amount of absorbed incident light to obtain a number proportional to the concentration of analyte per unit blood volume.
- the method can be performed while the region of tissue is in a blood-replete state and while the region of tissue is in a blood-depleted state.
- the net collected Raman spectra is divided by the net absorbed light, wherein net refers to the difference between the blood- replete and blood-depleted states.
- the spectra collected can be further enhanced by the adjacent averaging smoothing operations described above.
- the method can further comprise irradiating the tissue with a second light source having a wavelength that corresponds to an isosbestic point for oxy-deoxyhemoglobin.
- the second light source can be, for example, a laser, a black body source or a light emitting diode (LED).
- the first light source has a wavelength of about 785 nm and the second light source has a wavelength of about 805 or about 808 nm.
- the invention further provides a method of detecting Raman spectra emitted by irradiated tissue of a subject.
- the method comprises irradiating the tissue with light and collecting emitted Raman spectra while blood flow to the tissue is restricted by a tourniquet; and irradiating the tissue with light and collecting emitted Raman spectra while blood flow to the tissue is not restricted by a tourniquet.
- the method further comprises subtracting the spectra collected; and analyzing the positive spectra remaining after the subtraction.
- the tissue is skin.
- the light preferably has a wavelength of about 785 nm to about 850 nm.
- the invention also provides a method of modulating blood volume in a region of tissue for spectroscopic measurement comprising applying an ultrasonic transducer to the region of tissue.
- an ultrasonic transducer to the region of tissue.
- multiple transducers are applied to the region of tissue.
- Figure 1 is a schematic representation of tissue modulation using traveling and standing pressure wave patterns produced by interference between ultrasonic acoustic waves.
- Figure 2 is a plot of raw spectral counts, in ten thousands, at Raman shifts shown in wavenumbers collected from a subject while having his finger pressed against the metal plate of the apparatus (lower trace) and while the finger was not pressed against the metal plate (upper trace).
- Figure 3 shows the difference between the upper trace (unpressed) of Figure 2 and the lower trace (pressed) of Figure 2.
- the area under this curve is proportional to blood volume in the region of the fingertip probed.
- Figure 4 is a plot generated by taking the raw data shown in Figure 2, performing a 101 point adjacent averaging smoothing operation, then subtracting the smoothed data from the raw data, and performing a 7 point adjacent averaging smoothing operation on the result.
- the upper trace (unpressed condition) has been shifted upward by 20,000 counts to avoid overlapping of the displayed traces.
- Figure 5 shows the difference between the two traces shown in Figure 4. This subtraction reveals Raman features attributable to blood.
- the ratio of this value to the area under the curve shown in Figure 4 corresponds to blood glucose concentration.
- Figure 6 shows the linear fit of integrated normalized units (Raman signal divided by blood volume) obtained by the methods employed as in Figures 1-4 for two diabetic and one normal subject plotted against actual blood glucose concentration (in mg/dl) measured from blood drawn from the same subjects and assayed by conventional techniques. Displayed are results of the linear regression analysis indicating a correlation of 0.89977, having a p value of less than 0.0001.
- FIG 7 is a schematic illustration of an apparatus used to collect the data shown in Figures 9-13.
- the finger 10 of a subject is placed under a light source 12, such as a flashlight, free-space coupled diode laser or fiber-coupled diode laser, and against a metal plate 14 having a hole or transparent region, at the other end of which is a lensed pickup diode 16 connected by wires 18 to an oscilloscope 20.
- a light source 12 such as a flashlight, free-space coupled diode laser or fiber-coupled diode laser
- a metal plate 14 having a hole or transparent region, at the other end of which is a lensed pickup diode 16 connected by wires 18 to an oscilloscope 20.
- Figure 8 is a cross-sectional view through the finger 10 shown in Figure 7, and showing the finger 10 up against the hole 22 in the metal plate 14 and the angle of the lensed pickup diode 16 positioned on a diode mount 24.
- Figure 9 shows light passing through a subject's finger placed on the apparatus shown in Figures 7 and 8 as measured using the lensed pickup diode 16 and plotted as millivolts over time, in seconds. As indicated in the Figure, between heartbeats, when less blood is present in the fingertip, more light passes through. Likewise, less light passes during beats and when more blood is present and absorbing light.
- Figure 10 shows data similar to that shown in Figure 9, except that the subject has alternated between pressing the finger against the plate and unpressing the finger.
- the finger When the finger is pressed against the metal plate, blood leaves the fingertip and more light passes through. Similarly, less light passes when the finger is unpressed and filled with blood. The difference between the traces in the pressed and unpressed states provides an alternate method of determining blood volume.
- Figure 11 shows data similar to that shown in Figure 9, except that the subject had run in place for a few seconds prior to data collection. This activity increased heart rate and the effect of increased heart rate on fluctuations in light passing through the finger confirms that the source of the signal detected in Figures 8 and 9 is indeed changes in blood volume as a function of heartbeats.
- Figure 12 shows spectral counts at wavenumbers ranging from about 380 to about 2000 collected from a fingertip in which blood volume was modulated with a tourniquet. Displayed are counts detected with the tourniquet in place subtracted from counts detected without the tourniquet. Note the negative-going peaks.
- Figure 13 shows light passing through the subject's finger as measured using the lensed pickup diode and plotted as millivolts over time, in seconds.
- the upper trace shows measurements taken with the tourniquet in place, and the lower trace shows measurements taken without the tourniquet.
- the invention provides methods for tissue modulation and for noninvasive spectroscopic analysis of mobile and immobile tissues in a subject.
- the invention disclosed herein is based on discovery of a mathematical algorithm for analysis of spectroscopic information relating to analytes in tissue subjected to tissue modulation. Spectroscopic measurements of the tissue can be taken while the tissue is in blood-replete and blood-depleted states that are created by tissue modulation.
- the methods can be used with noninvasive spectroscopy such as Raman, absorption and fluorescence, and for the analysis of various features of tissue, including skin and blood.
- the invention provides methods that subtract effects due to extraneous factors such as skin imperfections and residue, and that isolate information related to blood volume and to blood analytes.
- the methods of the invention allow a direct subtraction of effects due to calluses, dirt, and soap residue, and other potential sources of extraneous spectroscopic signals.
- the method can apply to absorption, fluorescence, Raman, Rayleigh, phosphorescence, nuclear magnetic resonance, dielectric loss and other types of spectroscopy in which the interaction of matter with electromagnetic radiation can be quantitated.
- the method allows isolation of effects that originate from interactions of blood from those interactions involving the surrounding tissue.
- the method allows temporal and spatial modulation of the spectroscopic signals thereby improving the signal to noise ratio of the measurement.
- tissue means any portion of an organ or system of the body, including, but not limited to, skin, capillary beds, blood, muscle, breast and brain.
- Raman spectra associated with refers to those emitted Raman spectra that one skilled in the art would attribute to that component.
- Those skilled in the art are aware of available libraries that catalog known Raman spectra.
- blood-replete refers to a state in which blood content through a tissue is unobstructed by, for example, vasoconstriction induced by cooling or the application of pressure.
- the blood replete state can be enhanced by conditions that increase vasodilatation, such as warming.
- blood-depleted refers to a state in which blood flow into a tissue is restricted and blood content is minimized.
- a blood depleted state can be achieved by, for example, cooling and/or applying pressure to the tissue, or by controlling blood flow into and out of tissue through the use of a tourniquet.
- region of tissue refers to an area of tissue that light penetrates, and from which a signal is collected.
- pressed refers to an area of tissue to which external pressure is applied.
- unpressed refers to an area of tissue that has no external source of pressure applied to it.
- a means at least one, and can include a plurality.
- spectroscopy is used to analyze a chemical sample
- systematic variation of the conditions of a measurement results in several types of variation of the spectroscopic signal, e.g. emission intensity, absorption strength.
- Modulation is often systematically applied to localize and control the spatial and temporal characteristics of the spectroscopic signals.
- the optics of skin influence such analyses.
- the outermost surface of the skin is called the stratum corneum and it consists of a layer of partially polymerized dead skin, which is ca. 10 microns thick. This layer terminates in contact with a 200 micron thick layer of living cells called the epidermis.
- the epidermis terminates in contact with another layer called the dermis. This is the deepest layer of the skin and it extends downward until it contacts the connective tissues, adipose tissue and muscle tissue, etc.
- the capillary bed is situated at the interface between the dermis and the epidermis. It consists of a plurality of high surface area structures, i.e.
- the real part of the index of refraction of each of the three layers of the skin is equal to between about 1.34 and about 1.55. Given that all of the tissues in question have a chemical composition of about 97% water, this is not very surprising. Because of the chemical and physical organization of the epidermis and the dermis, i.e. consisting of collagen and elastin fibers imbedded in a matrix of living cells, melanin-containing granules and interstitial fluids, the optics of the skin is dominated by Mie scattering. This means that most incident light with wavelength greater than about 600 nm is elastically scattered off of objects of similar size, i.e. without any wavelength shift, and with a spatial preference in the forward direction.
- the invention provides a number of methods for tissue modulation.
- the underlying strategy is to change the blood volume of a region so that spectroscopic measurements can be made with a minimum or a maximum of blood volume present. Subtraction of signals corresponding to a minimum of blood present, from those corresponding to a maximum of blood present, allows isolation of the signal associated with the blood.
- the invention relates to the use of various means to manipulate and thereby modulate, temporally and spatially, the blood content of a selected portion of capillary bed, and methods of isolating the signal associated with the blood.
- tissue modulation includes using temperature and mechanical pressure, either by themselves or in concert, to control the blood content of a target capillary bed.
- Thermally induced vasoconstriction and vasodilatation are natural means for tissue modulation. Cooling the skin causes the associated capillaries to constrict, thereby squeezing the blood out of the cooled region. Warming the skin causes the capillaries to dilate and become flooded with blood.
- a very direct approach is for a person to press the finger tip, i.e. the fleshy side opposite the fingernail, against a clear substrate. Simply looking through a glass substrate, one can regulate the pressure so that a white region is visible where the skin is in contact with the glass, indicative of having driven the blood out of the pressurized region. It is easy to make a region uniformly white.
- This approach is advantageous in its simplicity and the absence of very specialized apparatus. It may be disadvantageous in that the spectroscopic probing of the tissue must occur through the glass substrate making it possible, depending on the type of spectroscopic measurement being conducted, that some type of background signal from the glass may also be unavoidable. Such problems are avoided by using a substrate having a hole that is smaller than the fingertip. The finger is pressed against the surface over the hole so as to modulate blood content in the tissue without interfering optically with the exposed surface of the fingertip.
- the invention provides methods for noninvasively measuring blood volume and analyte concentration and for obtaining spectroscopic information relating to immobile tissues, such as skin.
- the invention provides a noninvasive method of determining concentration of an analyte in blood of a subject.
- the subject is preferably a vertebrate, such as a mammal, bird, reptile or fish.
- mammals include, but are not limited to, human, bovine, porcine, ovine, murine, equine, canine, and feline.
- the subject is human.
- analytes include, but are not limited to, glucose, urea, creatinine, total protein, free fatty acids, monoglycerides, diglycerides, triglycerides, creatinine, alpha helix exposed exchangeable protein associated amide protons, cholesterol, pyruvate, tyrosine, tryptophan, bicarbonate, electrolytes, lactic acid, drugs and blood gases such as 0 2 , C0 2 and NO.
- the analyte is glucose.
- the method comprises irradiating a region of tissue, such as a fingertip, of the subject with a light source; collecting fluorescence spectra emitted by the region of tissue, the quantity of fluorescence spectra being indicative of blood volume; and collecting Raman spectra emitted by the region of tissue at a wavelength range that corresponds to the analyte, the quantity of Raman spectra being indicative of the amount of analyte.
- the collected spectra are then wavelength-resolved.
- the method further comprises dividing the collected Raman spectra by the collected fluorescence spectra to obtain the concentration of analyte per unit blood volume.
- the fluorescence and Raman spectra are collected while the region of tissue is in a blood-replete state and collected while the region of tissue is in a blood-depleted state.
- the method further comprises determining the integral of net collected spectra, net collected spectra being a difference between spectra collected while the region of tissue is in a blood-replete state and spectra collected while the region of tissue is in a blood-depleted state.
- the integral of the net collected Raman spectra at the wavelength range corresponding to the analyte is divided by the integral of the net collected fluorescence spectra.
- the net collected Raman spectra is determined by:
- I( ⁇ ) unp - I( ⁇ ) pre ⁇ ( ) + ft) + (V) + (CU + ftJ + CU» e- [bunp]d
- I( ⁇ ) collected light intensity at wavelength ⁇
- unp or u refers to an unpressed or blood-replete state
- pre or p refers to a pressed or blood-depleted state
- the method can further comprise enhancing the spectra collected by performing a 61-501 point adjacent averaging smoothing operation on the net collected spectra; subtracting the smoothed spectra from the net collected spectra; and performing a 3-27 point adjacent averaging smoothing operation on the result.
- the adjacent averaging smoothing operation of the first step is a 85-201 point smoothing operation, and more preferably, a 101 point smoothing operation.
- the adjacent averaging smoothing operation of the third step is preferably a 7 point smoothing operation.
- the light source emits light having a wavelength of about 785 nm to about 850 nm.
- a wavelength of 785 nm provides optimal overlap with sensitivity curve of the currently preferred silicon CCD array detector.
- 805 and 808 nm are desirable because these wavelengths are absorbed equally by oxy- and deoxy-hemoglobin. 808 nm is convenient for making the diode.
- One example of a light source is a laser. Examples of lasers suitable for use in producing an excitation wavelength include, but are not limited to, external cavity diode lasers, dye lasers, optimal parametric oscillators, and diode pumped solid state lasers.
- the blood-depleted state can be achieved by tissue modulation, including by applying a tourniquet to the tissue, by pressing the tissue against a surface, or by applying an ultrasonic transducer to the region of tissue.
- the invention also provides a noninvasive method of determining concentration of an analyte in blood of a subject that comprises irradiating a region of tissue of the subject with a light source; collecting Raman spectra emitted by the region of tissue at a wavelength range that corresponds to the analyte, the quantity of Raman spectra being indicative of the amount of analyte; and measuring absorption of incident light by the region of tissue, the amount of absorbed light being indicative of blood volume.
- the method further comprises dividing the collected Raman spectra by the amount of absorbed incident light to obtain the concentration of analyte per unit blood volume.
- the method can be performed while the region of tissue is in a blood-replete state and while the region of tissue is in a blood-depleted state.
- the net collected Raman spectra is divided by the net absorbed light, wherein net refers to the difference between the blood-replete and blood-depleted states.
- the spectra collected can be further enhanced by the adjacent averaging smoothing operations described above.
- the method can further comprise irradiating the tissue with a second light source having a wavelength that corresponds to an isosbestic point for oxy-deoxyhemoglobin, such as 805 or 808 nm.
- the second light source can be, for example, a laser, a black body source or a light emitting diode (LED).
- a filter can be used with a black body source to achieve wavelength selection.
- the first light source has a wavelength of about 785 nm and the second light source has a wavelength of about 805 or about 808 nm.
- the invention further provides a method of detecting Raman spectra emitted by irradiated tissue of a subject.
- the method comprises irradiating the tissue with light and collecting emitted Raman spectra while blood flow to the tissue is restricted by a tourniquet; and irradiating the tissue with light and collecting emitted Raman spectra while blood flow to the tissue is not restricted by a tourniquet.
- the method further comprises subtracting the spectra collected; and analyzing the positive spectra remaining after the subtraction.
- the tissue is skin. Other tissues can be used, such as ear lobe, muscle, breast or brain.
- the light preferably has a wavelength of about 785 nm to about 850 nm.
- the invention also provides a method of modulating blood volume in a region of tissue for spectroscopic measurement comprising applying an ultrasonic transducer to the region of tissue.
- an ultrasonic transducer to the region of tissue.
- multiple transducers are applied to the region of tissue.
- Example 1 Analysis of Spectroscopic Data Related to Analytes Whose Signal is Not Absorbed by Blood
- This Example describes an algorithm for use in analyzing data collected using the noninvasive methods of the invention.
- the algorithm is applicable to methods employing tissue modulation to achieve blood-replete and blood-depleted states. Spectra are collected in both the blood-replete and blood-depleted states so that information about the volume of blood probed can be obtained. Likewise, tissue modulation facilitates analysis of components present in the blood.
- the algorithm of this Example is particularly suited for conditions in which the blood does not absorb the signal associated with the analyte of interest.
- S y ⁇ (M) represent a measured value for some spectroscopic quantity indicative of the presence of a component or analyte ⁇ , e.g. glucose.
- S ⁇ (M) is proportional to the measured absorption at a given wavelength ⁇ , the scattered intensity of light at wavelength ⁇ , the intensity of fluorescence at wavelength ⁇ or other relevant measure.
- B ⁇ (M) represents total volume of blood measured in an area probed (e.g., hematocrit). M is the fraction of the total normal blood volume that is present in the spatial region probed when S ⁇ (M) is measured. Thus, M can vary between 0 and 1.0 and the object of tissue modulation is to manipulate the value of M.
- B ⁇ (5 (M) and S y ⁇ (M) are assigned the value of a spectroscopic measurement that is proportional to the volume of blood in the region probed.
- the spatial region and relative timing of the B y ⁇ (M) and S ⁇ (M) measurements are chosen to allow both measurements to be deterministically and quantitatively associated to the same blood volume.
- the objective is to obtain a consistent relationship between the volumes of blood and of analyte. They need not be measured at the same wavelengths since they need not be associated with the same kind of measurement.
- S ⁇ (M) could be associated with a Raman spectroscopic measurement and B ⁇ (M) could be absorption based. Small amounts of nonlinearity can be tolerated between the spectroscopic measurements and the concentration or blood volume so long as the dependencies can be parameterized.
- equation (1) is used to associate the B measurements with the volume of blood present in the probed region.
- the actual volume of blood, ⁇ (in units of cc or hematocrit), is proportional to the difference between the measurements B y(S in the pressurized (M ⁇ 0.0) and unpressed (M ⁇ 1.0) states.
- equation (2) expresses the quantity of the component
- ⁇ present in the same blood volume, in terms of being proportional to the difference between the measurements S y ⁇ in the pressed (M — 0. 0) and unpressed (M ⁇ 1.0) states.
- K K' ' /ic'
- the concentration has units of quantity of component ⁇ per volume of blood present, as does ⁇ / ⁇ .
- K is a proportionality constant which is a function of the sensitivities of the raw blood volume and analyte concentrations and other characteristics of the measurement processes, K is constant for a particular measurement apparatus. To the extent that the apparatus obtains a value for the blood concentration of ⁇ , there should be little dependence of the value of K on the exact sample of tissue used.
- B ⁇ (i (0) and S ⁇ (0) are measured on tissue that is under appropriate external pressure to drive blood out of the region probed.
- B y ⁇ ⁇ (1) and S ⁇ (l) are measured on tissue that has no applied external pressure.
- the blood present in the region probed is mostly a function of the differential between body temperature and ambient external temperature, the distance from the heart to the capillary bed in question, and the state of vasoconstriction/dilation of the local capillary beds.
- a DC measurement will be adequate.
- the need to make optical contact with the skin while simultaneously maintaining the pressed condition (M ⁇ 0) for a sufficiently long duration to allow sufficient signal accumulation requires special means to accomplish tissue modulation.
- modulation is performed at higher frequencies due to signal to noise considerations.
- Higher frequency modulation allows a bandwidth reduction in the detection of spectroscopic signals that leads directly to improvement in the net signal to noise ratio.
- Higher frequency modulation allows for subtraction between the pressed and unpressed states in an analog fashion, with resultant improvements in signal to noise ratio.
- the mechanical properties of the tissue, such as the capillaries and surrounding tissues, combine with the pumping properties of the circulatory system to limit the rapidity with which one can modulate the blood contents of a particular capillary bed.
- Sound waves are periodic pressure fluctuations and can be used to achieve tissue modulation for spectroscopic applications.
- Ultrasound has been used for a variety of biomedical applications including subdermal imaging, transdermal drug delivery, and subdermal heating therapy.
- ultrasonic waves from one or more transmitters are used to manipulate the contents of the capillary bed so that it may be spectroscopically probed using electromagnetic radiation.
- a single ultrasonic transducer is used, and the wave field produced in the region immediately adjacent to the transducer defines the region to be examined spectroscopically.
- the region of the wave field can be made more or less blood-depleted by increasing or decreasing the intensity of the ultrasound.
- simply turning the transmitter off allows blood to refill the region under normal heart beating thereby reproducing the blood-replete state.
- Blood tissues are not able to respond to the ultrasonic pressure at the same frequency as the ultrasonic pressure waves/fluctuations themselves. These frequencies range from roughly 10 1 KHz to the 10 1 MHz range, with displacements of 0.01 to 1.0 ⁇ m and across the entire ultrasonic frequency range, mass transfer of objects as large and heavy as erythrocytes will not occur on the timescale of the pressure fluctuations of the individual waves. However, the blood fluids and cells will respond on a much slower timescale to the greater average pressure in the ultrasonically irradiated tissue as compared to the surrounding tissues. It is this average pressure difference that provides the impetus for tissue modulation. Those skilled in the art will appreciate that impedance matching and other geometrical factors will play a role in determining the most advantageous frequency range to effect tissue modulation in a particular situation.
- the single transducer multipass approach is particularly suited to modulating the tissues of finger tips because simple well known anatomy provides a bone within about 1 cm of the transducer.
- the waves propagate from the transducer, enter the tissue through the skin, propagate through the underlying tissue including the capillary bed to the bone, reflect off the bone, propagate back through the same tissue including the capillary bed and then encounter the skin.
- Some of the waves reflect off the skin surface and reenter the tissues with an inward propagation vector whereas the rest scatter off the skin-air interface and dissipate into all directions.
- the constructive and destructive interference between the reflected wave field and the incident wave field provides regions of higher and lower pressure than is achievable using the single-pass approach.
- the overall effect is that the average net pressure is greater than that obtained in a single pass, thus improving the efficiency of the tissue modulation.
- the wavelength of the ultrasound ranges from a fraction of a millimeter to a few millimeters and to a certain extent this defines the size of the region that can be tissue modulated.
- the size of the glow-ball produced in tissue by a moderately focussed near infrared laser is on the order of 100 ⁇ m to 2 mm depending on the wavelength, and to some extent this defines the size of the region which requires tissue modulation. Properties of the light collection system are also important in this respect.
- a preferred embodiment provides the use of ultrasonic transducers to propagate sound waves into a chosen capillary bed such that standing and traveling wave patterns occur.
- the waves produce the appropriate tissue modulation.
- This modulation can be established in spatially and temporally advantageous patterns due to considerable latitude in choices of wavelength, polarization, and amplitude of the ultrasonic waves.
- Hard tissues such as bones in the vicinity of the chosen capillary bed can act like a mirror in setting up interference patterns that can be exploited in other tissue modulation schemes.
- multiple transducers or transmitters can be incorporated.
- the multiple transducer approach resembles the single transducer-multipass approach in that interference is used to achieve greater temporal and spatial control of the tissue modulation pattern.
- Multiple transducers can be used to generate additional pressure over a single transducer. Because transducers can be produced in various shapes and with various polarization, those skilled in the art will appreciate that there is considerable latitude in designing particular elements of an ultrasonic tissue modulator.
- the shape of the orifice used in current tissue modulator prototypes can also determine the spatial pattern for deploying the ultrasonic transducers.
- Figure 1 is a schematic representation of tissue modulation using traveling and standing pressure wave patterns produced by interference between ultrasonic acoustic waves.
- Example 3 Analysis of Spectroscopic Data by Compensating for Effect of Blood Content on Analyte Signal
- This Example describes another algorithm for use in analyzing data collected using the noninvasive methods of the invention.
- This algorithm is also applicable to methods employing tissue modulation to achieve blood-replete and blood-depleted states. Spectra are collected in both the blood-replete and blood-depleted states so that information about the volume of blood probed can be obtained. Likewise, tissue modulation facilitates analysis of components present in the blood.
- the algorithm of this Example is particularly suited for conditions in which the blood absorbs some of the signal associated with the analyte of interest, and compensates for the effects of this absorption on the analyte-related signal.
- Mie scattering is an elastic process that has a strong preference for producing a scattered wave in the forward direction.
- a "glow ball" of light is formed that is well represented as if the light propagates as in a random walk once it penetrates the first micron or so of the stratum corneum. This process involves, and results in, no wavelength shift for the scattered radiation.
- Rayleigh scattered light and the Mie scattered light can be differentiated on the basis of the much stronger preference for forward angles of the Mie process.
- the first is fluorescence and the second is Raman scattering. Both have similar angular dependencies on the incident light with both being much more isotropic than the Mie process.
- the amount, i.e. parameterization, of fluorescence is proportional to the intensity of the incident light, the absorption strength, the concentration of the absorber and the quantum yield for emitting fluorescence.
- Raman scattering intensity can be parameterized in terms of the concentration of scattering centers, the cross-section for scattering with a particular wavelength shift, and the intensity of the incident exciting radiation.
- Fluorescence is fundamentally a broadband emission producing light having a relatively smooth spectral distribution spread over at least 10 1 to 10 2 nanometers. In contrast, Raman scattering is typically spread over a narrow range of wavelengths (about 50 cm "1 at 785 nm).
- [s] concentration/ molarity of "skin” integrated over effective "glow- ball” (i.e. per volume element)
- [b] concentration/ molarity of "blood” integrated over effective "glow- ball” (i.e. per volume element)
- Y s quantum yield for fluorescence for skin (includes absorption coefficient)
- T b quantum yield for fluorescence for blood (includes absorption coefficient)
- the total amount of scattered/fluorescence light is around a factor of two to three orders of magnitude diminished from Ig so any so-called "stimulated" Raman effects (dependent on Raman scattered light not from I 0 but from Raman scattered light from I Q ) can be ignored.
- the chromophore e.g. oxyhemoglobin/deoxyhemoglobin is a large molecule and the transition is electronic/ vibronic, all absorption is broadband and related to the strength and features of the fluorescence as well.
- emission from a volume element at a particular depth that is not under any external tissue modulating stimulus is diminished using (following St. Jacques or Anderson and Parrish) the Beer's Law inspired exponential:
- Equation 1 would correspond to the expected emission from a volume element in which the tissue can be considered "blood replete". This in turn corresponds to the situation which prevails when a Raman spectrum is taken from a finger tip in the current tissue modulator in the "unpressed" condition.
- the blood content in the interaction volume can be represented as b unp .
- the tissue modulated spectrum of mobile components will therefore be enriched in the spectrum of blood compared to interstitial fluid.
- the spectrum produced by Raman scattering in the stratum corneum and the upper epidermis itself, i.e. all tissues from the upper edge of the shallowest capillary bed to the surface of the stratum corneum, is not affected by the presence or absence of blood. This can be seen by integrating equation 4 over the interval, 0 ⁇ d ⁇ approximately 150-200 ⁇ m. Raman scattered light can enter the collection cone without traversing any capillary bed and so the contribution this region makes to spectra of both blood-depleted and blood-replete finger tips will be substantially eliminated by subtraction of pressed from unpressed conditions. This is not the case for deeper tissues that are at or below the capillary bed and whose emission, which actually arrives at the skin surface, has been substantially filtered by the local blood supply.
- the absorption measurement which is taken to be a measure of blood volume, is independent of the degree of oxygenation of the blood.
- the degree of oxygenation is changing over the course of the Raman measurement, so another wavelength could be used.
- the blood volume measurement would then be averaged over many heart pulse cycles and, if there were any unusual variations in blood oxygen, then the blood volume measurement could be affected.
- Using an isosbestic point wavelength eliminates this possibility.
- Equation 6 can be averaged or integrated over the distribution of d values consistent with the dimensions of the glow-ball. In many cases this integral can be obtained in closed form but, if needed, it can always be obtained numerically.
- the exponential multiplying the entire sum has a different wavelength dependence than do the other terms (fluorescence and scattered wavelengths) since it only applies to the incident wavelength ⁇ g.
- the integral will be over three linear dimensions, i.e. dx,dy,dz or the equivalent in whatever coordinates are convenient (perhaps d, ⁇ , ⁇ ) and so will introduce a term corresponding to:
- tissue modulated Raman spectrum (a spectrum via the ⁇ ( ⁇ ), ]7( ⁇ ) terms) can be represented as:
- equation 6 a measured tissue modulated spectrum ( ) is proportional to the total amount of each substance in the interaction volume, V. It contains a sum of terms which are linear in concentrations, i.e. [b] and [s], and do not contain the integration variable.
- equation 6 is independent of two of the integration variables.
- a Taylor series expansion of the exponential has a leading term linear in d which, for small d, contributes to the weighting.
- V moles.
- V need not be exactly equal to V so long as it overlaps the analyte interaction volume substantially and thereby does in fact sample the environment responsible for the other [b] analyte related signals. It is particularly advantageous for V to be measured using a ⁇ having similar penetration characteristics as that used to obtain a signal for the analyte [b]. As will be shown below, this leads to a better cancellation of deviations from the Taylor series expansion.
- Equation 6 is completely general in that the Raman cross-section can be chosen to correspond to a particular analyte [b].
- concentrations i.e. an expression in terms of measurable quantities for [b]
- the integral of J>( ⁇ ) is divided over a suitable interval containing ⁇ g by V. That is:
- C represents the calibration constant associated with a particular alignment/instrument and user. So long as C is constant, corresponding to a constant degree of spatial overlap between the actual weighted volumes (blood and analyte volumes) interrogated by light, inspection of equation 6 shows that the instrument/measurement process produces a spectrum in which the integrals over scattering wavelength shift are sums of contributions each of which is proportional to concentrations of blood and tissue components, i.e. [b] and [s] respectively. In reality, of course, there may be more than one analyte contributing to the scattered intensity at any particular Raman shift but the main point is that the scattered intensity and the fluorescence intensity is proportional to the concentration of analytes. Blood volume measurement can be conveniently made using the fluorescence of blood and tissues.
- ⁇ 0 say 785 nm or 805 nm
- V blood volume
- sufficient fluorescence is produced to allow blood volume estimation while still not obscuring the Raman features.
- fluorescence is broadband emission whereas Raman is narrow.
- [b] can be either something that is proportional to the hematocrit, i.e. hemoglobin content, or it could be another analyte, b'.
- [b] is used to acknowledge that the majority of the fluorescence is known to come from the blood and the so the fluorescence is a good measure of blood volume [b] ⁇ V , i.e. the integral of ( ⁇ ) over a wide interval in ⁇ , is a good measure of blood volume, i.e. V.
- This Example demonstrates that the noninvasive analysis methods disclosed above can be used to obtain blood glucose measurements that very closely approximate measurements taken from the same subjects using conventional, invasive techniques.
- This Example also demonstrates the use of fluorescence-based blood volume determinations, as well as the enhancement of spectral information using the smoothing operations disclosed above.
- the apparatus included a light source, a metal plate having a hole through which incident and emitted light could pass, a detector, and a signal processor. Suitable components and specific embodiments of the apparatus can be adapted from other Raman spectroscopy systems known in the art (see, e.g., U.S. Patent Nos. 5,553,616; 5,510,894; 5,615,673; and 5,551,422).
- the edge of the hole in the metal plate was the surface against which the finger was pressed in order to modulate blood content in the tissue probed.
- the light source was an external cavity diode laser emitting at 785 nm (SDL, Inc., Santa Clara, CA).
- the detector was a CCD array (Princeton Instruments, Trenton, NJ). Light was collected by 250 mm fl.4 Nikon lenses. Light was first filtered by a holographic notch filter and dispersed by a holographic spectrograph (both from Kaiser Optical Systems, Ann Arbor, MI). Signal processing was performed with a standard personal computer. Subjects placed a fingertip against a V* inch hole in an aluminum plate, alternating between pressing against the plate to achieve a blood-depleted state and releasing pressure against the plate to achieve a blood-replete state. Incident light at 785 nm was passed through the hole in the metal plate to the subject's fingertip, and collected spectra were analyzed as described below. Light was focused onto the finger with a 13 cm focal length piano convex lens. Incident laser power at the finger tip was 50 mWatts and the spectral bandwidth was approximately 1 cm '1 .
- Figure 2 shows representative raw spectral counts, in ten thousands, at Raman shifts shown in wavenumbers collected from a subject while having his finger pressed against the metal plate of the apparatus (lower trace) and while the finger was not pressed against the metal plate (upper trace).
- Figure 3 shows the difference between the upper trace (unpressed) of Figure 2 and the lower trace (pressed) of Figure 2. The area under this curve is proportional to blood volume variation in the region of the fingertip probed due to tissue modulation.
- Figure 4 is a plot generated by taking the raw data shown in Figure 2, performing a 101 point adjacent averaging smoothing operation, then subtracting the smoothed data from the raw data, and performing a 7 point adjacent averaging smoothing operation on the result.
- the upper trace (unpressed condition) has been shifted upward by 20,000 counts to avoid overlapping of the displayed traces.
- Figure 5 shows the difference between the two traces shown in Figure 4. This subtraction reveals Raman features attributable to blood.
- the area between the curve and zero in the region between 495 and 560 wavenumbers (arrow) was integrated to obtain a measure corresponding to blood glucose content.
- the ratio of this value to the area under the curve (yielding normalized integrated units) shown in Figure 4 is proportional to blood glucose concentration.
- Figure 6 shows the linear fit of integrated normalized units (Raman signal divided by blood volume) obtained for two diabetic and one normal subject plotted against actual blood glucose concentration (in mg/dl) measured from blood drawn from the same subjects and assayed by a physician using a HemaCueTM kit (HemaCue, Inc., Mission Viejo, CA) following manufacturer's instructions. Displayed are results of the linear regression analysis indicating a correlation of 0.89977, having a p value of less than 0.0001.
- Example 5 Absorption-Based Blood Volume Measurements from a Human Subject
- This Example demonstrates that blood volume information can be derived from measuring absorption of light by the blood.
- the Example includes demonstrations that the signal is altered by known alterations in blood volume due to heartrate.
- FIG. 7 A schematic illustration of the apparatus used to collect the data is shown in Figure 7.
- the finger 10 of a subject was placed under a light source 12, e.g., a flashlight, free-space coupled 805 nm diode laser or fiber-coupled 805 nm diode laser (all three were used in different experiments), and against a metal plate 14 having a hole, at the other end of which is a lensed pickup diode (GaAs) 16 connected by wires 18 to an oscilloscope 20.
- Figure 8 is a cross-sectional view through the finger 10 shown in Figure 7, and shows the finger 10 up against the hole 22 in the metal plate 14 and the angle of the lensed pickup diode 16 positioned on a diode mount 24.
- Figure 9 shows light passing through a subject's finger placed on the apparatus measured using the lensed pickup diode 16 and plotted as millivolts over time, in seconds.
- Figure 10 shows data similar to that shown in Figure 9, except that the subject has alternated between pressing the finger against the plate and unpressing the finger. When the finger is pressed against the metal plate, blood leaves the fingertip and more light passes through. Similarly, less light passes when the finger is unpressed and filled with blood. The difference between the traces in the pressed and unpressed states provides an alternate method of determining blood volume.
- Figure 11 shows data similar to that shown in Figure 9, except that the subject had run in place for a few seconds prior to data collection.
- This activity increased heart rate and the effect of increased heart rate on fluctuations in light passing through the finger confirms that the source of the signal detected in Figures 8 and 9 is indeed changes in blood volume as a function of heartbeats.
- Figure 12 shows spectral counts at wavenumbers ranging from about 380 to about 2000 collected from a fingertip in which blood volume was modulated with a tourniquet. Displayed are counts detected with the tourniquet in place subtracted from counts detected without the tourniquet. Note the negative-going peaks.
- Figure 13 shows light passing through the subject's finger as measured using the lensed pickup diode and plotted as millivolts over time, in seconds.
- the upper trace shows measurements taken with the tourniquet in place, and the lower trace shows measurements taken without the tourniquet.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002333565A CA2333565C (en) | 1998-07-07 | 1999-07-07 | Tissue modulation process for quantitative noninvasive in vivo spectroscopic analysis of tissues |
AU49704/99A AU4970499A (en) | 1998-07-07 | 1999-07-07 | Tissue modulation process for quantitative noninvasive in vivo spectroscopic analysis of tissues |
AT99933705T ATE225142T1 (en) | 1998-07-07 | 1999-07-07 | TISSUE MODULATION METHOD FOR QUANTITATIVE NON-INVASIVE IN VIVO SPECTROSCOPIC ANALYSIS OF TISSUE |
DE69903306T DE69903306T2 (en) | 1998-07-07 | 1999-07-07 | METHOD FOR TISSUE MODULATION FOR QUANTITATIVE NON-INVASIVE IN VIVO SPECTROSCOPIC ANALYSIS OF TISSUE |
EP99933705A EP1094746B1 (en) | 1998-07-07 | 1999-07-07 | Tissue modulation process for quantitative noninvasive in vivo spectroscopic analysis of tissues |
JP2000557746A JP4486253B2 (en) | 1998-07-07 | 1999-07-07 | Sample concentration determination device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9189998P | 1998-07-07 | 1998-07-07 | |
US60/091,899 | 1998-07-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000001295A1 true WO2000001295A1 (en) | 2000-01-13 |
WO2000001295A8 WO2000001295A8 (en) | 2000-03-23 |
Family
ID=22230207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/015217 WO2000001295A1 (en) | 1998-07-07 | 1999-07-07 | Tissue modulation process for quantitative noninvasive in vivo spectroscopic analysis of tissues |
Country Status (9)
Country | Link |
---|---|
US (1) | US6289230B1 (en) |
EP (1) | EP1094746B1 (en) |
JP (1) | JP4486253B2 (en) |
AT (1) | ATE225142T1 (en) |
AU (1) | AU4970499A (en) |
CA (1) | CA2333565C (en) |
DE (1) | DE69903306T2 (en) |
ES (1) | ES2185374T3 (en) |
WO (1) | WO2000001295A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001010294A1 (en) * | 1999-08-10 | 2001-02-15 | Gesellschaft zur Förderung der Spektrochemie und angewandten Spektroskopie e.V. | Method and device for measuring blood fractions and clinical parameters in a non-invasive manner |
WO2002003857A2 (en) * | 2000-07-11 | 2002-01-17 | Lightouch Medical, Inc. | Method of tissue modulation for noninvasive measurement of an analyte |
US6711426B2 (en) | 2002-04-09 | 2004-03-23 | Spectros Corporation | Spectroscopy illuminator with improved delivery efficiency for high optical density and reduced thermal load |
WO2006002452A1 (en) * | 2004-07-05 | 2006-01-12 | Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung | Raman spectroscopic device and method |
WO2007128533A2 (en) * | 2006-05-05 | 2007-11-15 | Mevitec Gmbh | Device and method for examining and evaluating a biologically active and/or activatable substance |
WO2009021178A1 (en) * | 2007-08-08 | 2009-02-12 | Chemimage Corporation | Raman difference spectra based disease classification |
US7813778B2 (en) | 2005-07-29 | 2010-10-12 | Spectros Corporation | Implantable tissue ischemia sensor |
EP1890133B1 (en) * | 2006-08-16 | 2016-10-12 | F. Hoffmann-La Roche AG | Method for analysing the sample of a liquid |
EP3641634A4 (en) * | 2017-06-20 | 2021-03-10 | I.R Med Ltd | System and method for noninvasive analysis of subcutaneous tissue |
US11020027B2 (en) | 2017-09-18 | 2021-06-01 | Samsung Electronics Co., Ltd. | Apparatus and method for estimating glucose exposure and generating glucose exposure estimation model |
Families Citing this family (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6389306B1 (en) * | 1998-04-24 | 2002-05-14 | Lightouch Medical, Inc. | Method for determining lipid and protein content of tissue |
JP2000155090A (en) * | 1998-11-20 | 2000-06-06 | Fuji Photo Film Co Ltd | Imaging device for blood vessel |
US20090059203A1 (en) * | 2000-03-17 | 2009-03-05 | Wei-Kung Wang | Apparatus For Measuring Concentration of a Specific Ingredient In-Situ |
US7389132B2 (en) * | 2000-03-17 | 2008-06-17 | Wei-Kung Wang | Mold-in method and apparatus |
US20060211931A1 (en) * | 2000-05-02 | 2006-09-21 | Blank Thomas B | Noninvasive analyzer sample probe interface method and apparatus |
US7606608B2 (en) * | 2000-05-02 | 2009-10-20 | Sensys Medical, Inc. | Optical sampling interface system for in-vivo measurement of tissue |
US7519406B2 (en) * | 2004-04-28 | 2009-04-14 | Sensys Medical, Inc. | Noninvasive analyzer sample probe interface method and apparatus |
DE10027100C2 (en) * | 2000-05-31 | 2002-08-08 | Klaus Mueller-Dethlefs | Method and device for detecting substances in body fluids |
AU2002236779A1 (en) * | 2001-01-19 | 2002-07-30 | General Instrument Corporation | Voice menu controlled self-diagnostic method |
US7004928B2 (en) | 2002-02-08 | 2006-02-28 | Rosedale Medical, Inc. | Autonomous, ambulatory analyte monitor or drug delivery device |
US8718738B2 (en) | 2002-03-08 | 2014-05-06 | Glt Acquisition Corp. | Method and apparatus for coupling a sample probe with a sample site |
MXPA04008713A (en) * | 2002-03-08 | 2006-02-24 | Sensys Medical Inc | Compact apparatus for noninvasive measurement of glucose through near-infrared spectroscopy. |
US20050187439A1 (en) * | 2003-03-07 | 2005-08-25 | Blank Thomas B. | Sampling interface system for in-vivo estimation of tissue analyte concentration |
US8504128B2 (en) * | 2002-03-08 | 2013-08-06 | Glt Acquisition Corp. | Method and apparatus for coupling a channeled sample probe to tissue |
US7697966B2 (en) * | 2002-03-08 | 2010-04-13 | Sensys Medical, Inc. | Noninvasive targeting system method and apparatus |
US20050054908A1 (en) * | 2003-03-07 | 2005-03-10 | Blank Thomas B. | Photostimulation method and apparatus in combination with glucose determination |
US20070149868A1 (en) * | 2002-03-08 | 2007-06-28 | Blank Thomas B | Method and Apparatus for Photostimulation Enhanced Analyte Property Estimation |
EP1498070A4 (en) | 2002-03-25 | 2007-05-02 | Tyt Inst Of Technology Corp | Noninvasive blood component value measuring instrument and method |
US8131332B2 (en) * | 2002-04-04 | 2012-03-06 | Veralight, Inc. | Determination of a measure of a glycation end-product or disease state using tissue fluorescence of various sites |
US7725144B2 (en) * | 2002-04-04 | 2010-05-25 | Veralight, Inc. | Determination of disease state using raman spectroscopy of tissue |
US7052652B2 (en) | 2003-03-24 | 2006-05-30 | Rosedale Medical, Inc. | Analyte concentration detection devices and methods |
US20070085995A1 (en) * | 2003-07-09 | 2007-04-19 | Glucon, Inc. | Wearable glucometer |
US20050043597A1 (en) * | 2003-07-31 | 2005-02-24 | Skymoon Research And Development, Llc | Optical vivo probe of analyte concentration within the sterile matrix under the human nail |
US7266401B2 (en) * | 2003-08-22 | 2007-09-04 | C8 Medisensors Inc. | Measuring analytes from an electromagnetic spectrum using a wavelength router |
US20070234300A1 (en) * | 2003-09-18 | 2007-10-04 | Leake David W | Method and Apparatus for Performing State-Table Driven Regression Testing |
US20050187438A1 (en) * | 2004-02-24 | 2005-08-25 | Skymoon Research & Development, Llc | Anti-stokes raman in vivo probe of analyte concentrations through the human nail |
US8868147B2 (en) * | 2004-04-28 | 2014-10-21 | Glt Acquisition Corp. | Method and apparatus for controlling positioning of a noninvasive analyzer sample probe |
US20080033275A1 (en) * | 2004-04-28 | 2008-02-07 | Blank Thomas B | Method and Apparatus for Sample Probe Movement Control |
US20060063993A1 (en) * | 2004-08-09 | 2006-03-23 | Dejin Yu | Method and apparatus for non-invasive measurement of blood analytes |
US20060063991A1 (en) * | 2004-08-09 | 2006-03-23 | Dejin Yu | Method and apparatus for non-invasive measurement of blood analytes with dynamic spectral calibration |
US20060063992A1 (en) * | 2004-08-09 | 2006-03-23 | Dejin Yu | Method and apparatus for non-invasive measurement of blood analytes |
US8234923B2 (en) | 2004-09-20 | 2012-08-07 | Innervision Medical Technologies Inc. | Systems and methods for ultrasound imaging |
GB0426993D0 (en) * | 2004-12-09 | 2005-01-12 | Council Cent Lab Res Councils | Apparatus for depth-selective raman spectroscopy |
WO2006074337A1 (en) * | 2005-01-06 | 2006-07-13 | Lightouch Medical, Inc. | Specialized human servo device and process for tissue modulation of human fingertips |
US20060206018A1 (en) * | 2005-03-04 | 2006-09-14 | Alan Abul-Haj | Method and apparatus for noninvasive targeting |
US20060211926A1 (en) * | 2005-03-21 | 2006-09-21 | Dejin Yu | Non-invasive Raman measurement apparatus with broadband spectral correction |
US8180422B2 (en) * | 2005-04-15 | 2012-05-15 | Bayer Healthcare Llc | Non-invasive system and method for measuring an analyte in the body |
WO2006127766A1 (en) * | 2005-05-25 | 2006-11-30 | Bayer Healthcare Llc | Methods of using raman spectral information in determining analyte concentrations |
US7330747B2 (en) * | 2005-06-07 | 2008-02-12 | Chemimage Corporation | Invasive chemometry |
US7330746B2 (en) * | 2005-06-07 | 2008-02-12 | Chem Image Corporation | Non-invasive biochemical analysis |
US20060281187A1 (en) | 2005-06-13 | 2006-12-14 | Rosedale Medical, Inc. | Analyte detection devices and methods with hematocrit/volume correction and feedback control |
EP2260756A1 (en) * | 2005-08-09 | 2010-12-15 | Flore, Ingo | Medical measuring device |
US8855738B2 (en) * | 2005-08-18 | 2014-10-07 | University Of Rochester | Acoustically induced blood stasis and in vivo optical spectroscopy |
EP1760440A1 (en) * | 2005-08-31 | 2007-03-07 | The Procter and Gamble Company | Confocal raman spectroscopy for dermatological studies |
US7914451B2 (en) * | 2005-09-15 | 2011-03-29 | Innervision Medical Technologies Inc. | Determining attributes using ultrasound |
US8801631B2 (en) | 2005-09-30 | 2014-08-12 | Intuity Medical, Inc. | Devices and methods for facilitating fluid transport |
US8382681B2 (en) | 2005-09-30 | 2013-02-26 | Intuity Medical, Inc. | Fully integrated wearable or handheld monitor |
US7558619B2 (en) * | 2005-10-04 | 2009-07-07 | Nu Skin International, Inc. | Raman instrument for measuring weak signals in the presence of strong background fluorescence |
GB0606891D0 (en) * | 2006-04-05 | 2006-05-17 | Council Cent Lab Res Councils | Raman Analysis Of Pharmaceutical Tablets |
US8105239B2 (en) | 2006-02-06 | 2012-01-31 | Maui Imaging, Inc. | Method and apparatus to visualize the coronary arteries using ultrasound |
US20100030480A1 (en) * | 2006-05-05 | 2010-02-04 | Jahn Wolfgang | Device and method for examination and evaluation of a biological active and/or biological activatable substance |
EP2077748A2 (en) * | 2006-08-22 | 2009-07-15 | Bayer Healthcare, LLC | A method for correcting a spectral image for optical aberrations using software |
US7603151B2 (en) * | 2006-08-22 | 2009-10-13 | Bayer Healthcare Llc | Non-invasive methods of using spectral information in determining analyte concentrations |
WO2008051639A2 (en) | 2006-10-25 | 2008-05-02 | Maui Imaging, Inc. | Method and apparatus to produce ultrasonic images using multiple apertures |
WO2008052221A2 (en) * | 2006-10-27 | 2008-05-02 | Aretais, Inc. | Use of coherent raman techniques for medical diagnostic and therapeutic purposes, and calibration techniques for same |
EP2096989B1 (en) * | 2006-11-23 | 2012-11-21 | Flore, Ingo | Medical measuring device |
US8157730B2 (en) * | 2006-12-19 | 2012-04-17 | Valencell, Inc. | Physiological and environmental monitoring systems and methods |
US8652040B2 (en) | 2006-12-19 | 2014-02-18 | Valencell, Inc. | Telemetric apparatus for health and environmental monitoring |
US8320982B2 (en) * | 2006-12-27 | 2012-11-27 | Valencell, Inc. | Multi-wavelength optical devices and methods of using same |
KR100871074B1 (en) * | 2007-02-01 | 2008-11-28 | 삼성전자주식회사 | Noninvasive apparatus and method for measuring blood glucose |
KR101312259B1 (en) * | 2007-02-09 | 2013-09-25 | 삼성전자주식회사 | Thin film transistor and method for forming the same |
US7672702B2 (en) * | 2007-03-13 | 2010-03-02 | Samsung Electronics Co., Ltd. | Noninvasive in vivo measuring system and noninvasive in vivo measuring method by correcting influence of Hemoglobin |
US20090036759A1 (en) * | 2007-08-01 | 2009-02-05 | Ault Timothy E | Collapsible noninvasive analyzer method and apparatus |
KR101629974B1 (en) * | 2007-09-07 | 2016-06-14 | 플로레, 잉고 | Medical measurement device for bioelectrical impedance measurement |
WO2009045374A2 (en) * | 2007-09-28 | 2009-04-09 | University Of Florida Research Foundation Inc. | Novel methods and devices for noninvasive measurement of energy absorbers in blood |
US9247926B2 (en) | 2010-04-14 | 2016-02-02 | Maui Imaging, Inc. | Concave ultrasound transducers and 3D arrays |
US9788813B2 (en) | 2010-10-13 | 2017-10-17 | Maui Imaging, Inc. | Multiple aperture probe internal apparatus and cable assemblies |
US9282945B2 (en) | 2009-04-14 | 2016-03-15 | Maui Imaging, Inc. | Calibration of ultrasound probes |
US8251903B2 (en) | 2007-10-25 | 2012-08-28 | Valencell, Inc. | Noninvasive physiological analysis using excitation-sensor modules and related devices and methods |
CA2725264C (en) | 2008-05-30 | 2017-06-20 | Intuity Medical, Inc. | Body fluid sampling device -- sampling site interface |
US8260402B2 (en) * | 2008-06-06 | 2012-09-04 | Longevity Link, Inc. | Noninvasive measurement of carotenoids in biological tissue |
EP2299904B1 (en) | 2008-06-06 | 2019-09-11 | Intuity Medical, Inc. | Medical measurement method |
US9636051B2 (en) | 2008-06-06 | 2017-05-02 | Intuity Medical, Inc. | Detection meter and mode of operation |
CN101292875B (en) * | 2008-06-06 | 2010-07-14 | 天津市先石光学技术有限公司 | Method for measuring component concentration with reference wavelength |
US9814417B2 (en) * | 2009-01-13 | 2017-11-14 | Longevity Link Corporation | Noninvasive measurement of flavonoid compounds in biological tissue |
US8788002B2 (en) | 2009-02-25 | 2014-07-22 | Valencell, Inc. | Light-guiding devices and monitoring devices incorporating same |
EP3357419A1 (en) | 2009-02-25 | 2018-08-08 | Valencell, Inc. | Light-guiding devices and monitoring devices incorporating same |
US9750462B2 (en) | 2009-02-25 | 2017-09-05 | Valencell, Inc. | Monitoring apparatus and methods for measuring physiological and/or environmental conditions |
DE102009011381A1 (en) | 2009-03-05 | 2010-09-09 | Flore, Ingo, Dr. | Diagnostic measuring device |
WO2010120907A2 (en) | 2009-04-14 | 2010-10-21 | Maui Imaging, Inc. | Multiple aperture ultrasound array alignment fixture |
US8538499B2 (en) * | 2009-09-23 | 2013-09-17 | Lightouch Medical, Inc. | Process and apparatus for non-invasive, continuous in vivo measurement of hematocrit |
WO2011065981A1 (en) | 2009-11-30 | 2011-06-03 | Intuity Medical, Inc. | Calibration material delivery devices and methods |
US9603559B2 (en) | 2009-12-24 | 2017-03-28 | Children's Medical Center Corporation | Capillary refill time diagnostic apparatus and methods |
WO2011103303A2 (en) | 2010-02-18 | 2011-08-25 | Maui Imaging, Inc. | Point source transmission and speed-of-sound correction using mult-aperture ultrasound imaging |
JP5441781B2 (en) * | 2010-03-25 | 2014-03-12 | キヤノン株式会社 | Photoacoustic imaging apparatus, photoacoustic imaging method, and program |
US8235897B2 (en) | 2010-04-27 | 2012-08-07 | A.D. Integrity Applications Ltd. | Device for non-invasively measuring glucose |
US10330667B2 (en) | 2010-06-25 | 2019-06-25 | Intuity Medical, Inc. | Analyte monitoring methods and systems |
US9662047B2 (en) | 2010-08-05 | 2017-05-30 | Massachusetts Institute Of Technology | Portable raman diagnostic system |
US10292589B2 (en) * | 2010-09-20 | 2019-05-21 | California Institute Of Technology | Acoustic-assisted iterative wave form optimization for deep tissue focusing |
US10216893B2 (en) | 2010-09-30 | 2019-02-26 | Fitbit, Inc. | Multimode sensor devices |
US8888701B2 (en) | 2011-01-27 | 2014-11-18 | Valencell, Inc. | Apparatus and methods for monitoring physiological data during environmental interference |
US9427191B2 (en) | 2011-07-25 | 2016-08-30 | Valencell, Inc. | Apparatus and methods for estimating time-state physiological parameters |
EP2739207B1 (en) | 2011-08-02 | 2017-07-19 | Valencell, Inc. | Systems and methods for variable filter adjustment by heart rate metric feedback |
JP6223337B2 (en) | 2011-08-03 | 2017-11-08 | インテュイティ メディカル インコーポレイテッド | Body fluid extraction measuring instrument |
EP2785253B1 (en) | 2011-12-01 | 2023-11-15 | Maui Imaging, Inc. | Motion detection using ping-based and multiple aperture doppler ultrasound |
WO2013101988A1 (en) | 2011-12-29 | 2013-07-04 | Maui Imaging, Inc. | M-mode ultrasound imaging of arbitrary paths |
KR102134763B1 (en) | 2012-02-21 | 2020-07-16 | 마우이 이미징, 인코포레이티드 | Determining material stiffness using multiple aperture ultrasound |
EP2833791B1 (en) | 2012-03-26 | 2022-12-21 | Maui Imaging, Inc. | Methods for improving ultrasound image quality by applying weighting factors |
US9044149B2 (en) | 2012-06-22 | 2015-06-02 | Fitbit, Inc. | Heart rate data collection |
US9049998B2 (en) | 2012-06-22 | 2015-06-09 | Fitbit, Inc. | Biometric monitoring device with heart rate measurement activated by a single user-gesture |
US8948832B2 (en) | 2012-06-22 | 2015-02-03 | Fitbit, Inc. | Wearable heart rate monitor |
US9005129B2 (en) | 2012-06-22 | 2015-04-14 | Fitbit, Inc. | Wearable heart rate monitor |
IN2015DN00556A (en) | 2012-08-10 | 2015-06-26 | Maui Imaging Inc | |
EP3893022A1 (en) | 2012-08-21 | 2021-10-13 | Maui Imaging, Inc. | Ultrasound imaging system memory architecture |
KR101390090B1 (en) * | 2012-09-18 | 2014-05-27 | 한국과학기술원 | Sensing apparatus for user terminal using camera, method for the same and controlling method for the same |
US9039614B2 (en) | 2013-01-15 | 2015-05-26 | Fitbit, Inc. | Methods, systems and devices for measuring fingertip heart rate |
ITMI20130104A1 (en) * | 2013-01-24 | 2014-07-25 | Empatica Srl | DEVICE, SYSTEM AND METHOD FOR THE DETECTION AND TREATMENT OF HEART SIGNALS |
WO2014116942A2 (en) | 2013-01-28 | 2014-07-31 | Valencell, Inc. | Physiological monitoring devices having sensing elements decoupled from body motion |
WO2014160291A1 (en) | 2013-03-13 | 2014-10-02 | Maui Imaging, Inc. | Alignment of ultrasound transducer arrays and multiple aperture probe assembly |
WO2014205412A1 (en) | 2013-06-21 | 2014-12-24 | Intuity Medical, Inc. | Analyte monitoring system with audible feedback |
US10512407B2 (en) | 2013-06-24 | 2019-12-24 | Fitbit, Inc. | Heart rate data collection |
US9883848B2 (en) | 2013-09-13 | 2018-02-06 | Maui Imaging, Inc. | Ultrasound imaging using apparent point-source transmit transducer |
EP3013217B1 (en) | 2014-01-07 | 2017-02-22 | Opsolution GmbH | Device and method for determining a concentration in a sample |
US9538921B2 (en) | 2014-07-30 | 2017-01-10 | Valencell, Inc. | Physiological monitoring devices with adjustable signal analysis and interrogation power and monitoring methods using same |
EP4098178B1 (en) | 2014-08-06 | 2024-04-10 | Yukka Magic LLC | Optical physiological sensor modules with reduced signal noise |
WO2016028787A1 (en) | 2014-08-18 | 2016-02-25 | Maui Imaging, Inc. | Network-based ultrasound imaging system |
US10772541B2 (en) * | 2014-08-21 | 2020-09-15 | I. R. Med Ltd. | System and method for noninvasive analysis of subcutaneous tissue |
US10709365B2 (en) | 2014-08-21 | 2020-07-14 | I. R. Med Ltd. | System and method for noninvasive analysis of subcutaneous tissue |
US9794653B2 (en) | 2014-09-27 | 2017-10-17 | Valencell, Inc. | Methods and apparatus for improving signal quality in wearable biometric monitoring devices |
GB201503911D0 (en) | 2015-03-09 | 2015-04-22 | Renishaw Plc | Transmission raman spectroscopy |
US9392946B1 (en) | 2015-05-28 | 2016-07-19 | Fitbit, Inc. | Heart rate sensor with high-aspect-ratio photodetector element |
US10610158B2 (en) | 2015-10-23 | 2020-04-07 | Valencell, Inc. | Physiological monitoring devices and methods that identify subject activity type |
US10945618B2 (en) | 2015-10-23 | 2021-03-16 | Valencell, Inc. | Physiological monitoring devices and methods for noise reduction in physiological signals based on subject activity type |
EP3170446A1 (en) * | 2015-11-20 | 2017-05-24 | NIRLUS Engineering AG | Method and device for the non-invasive optical in-vivo determination of glucose concentration in flowing blood |
US11206989B2 (en) | 2015-12-10 | 2021-12-28 | Fitbit, Inc. | Light field management in an optical biological parameter sensor |
US10568525B1 (en) | 2015-12-14 | 2020-02-25 | Fitbit, Inc. | Multi-wavelength pulse oximetry |
CN108601529B (en) | 2015-12-31 | 2022-02-25 | 威尔图比有限公司 | Apparatus, system and method for non-invasive monitoring of physiological measurements |
CN113729764A (en) | 2016-01-27 | 2021-12-03 | 毛伊图像公司 | Ultrasound imaging with sparse array probe |
US10433739B2 (en) | 2016-04-29 | 2019-10-08 | Fitbit, Inc. | Multi-channel photoplethysmography sensor |
US10966662B2 (en) | 2016-07-08 | 2021-04-06 | Valencell, Inc. | Motion-dependent averaging for physiological metric estimating systems and methods |
US11051706B1 (en) | 2017-04-07 | 2021-07-06 | Fitbit, Inc. | Multiple source-detector pair photoplethysmography (PPG) sensor |
KR20200097144A (en) | 2019-02-07 | 2020-08-18 | 삼성전자주식회사 | Apparatus and method for estimating bio-information |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0623308A1 (en) * | 1993-05-07 | 1994-11-09 | Diasense, Inc. | Method for non-invasive measurement of concentration of constituents in blood |
US5372135A (en) * | 1991-12-31 | 1994-12-13 | Vivascan Corporation | Blood constituent determination based on differential spectral analysis |
DE19518511A1 (en) * | 1994-05-20 | 1995-11-23 | Hermann Dipl Ing Kuenst | Non-invasive, transcutaneous measurement of substances in blood |
US5510894A (en) | 1988-12-22 | 1996-04-23 | Renishaw Plc | Spectroscopic apparatus and methods |
US5551422A (en) | 1992-11-09 | 1996-09-03 | Boehringer Mannheim Gmbh | Method and apparatus for analytical determination of glucose in a biological matrix |
US5553616A (en) | 1993-11-30 | 1996-09-10 | Florida Institute Of Technology | Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator |
WO1996039926A1 (en) * | 1995-06-07 | 1996-12-19 | Masimo Corporation | Active pulse blood constituent monitoring |
US5615673A (en) | 1995-03-27 | 1997-04-01 | Massachusetts Institute Of Technology | Apparatus and methods of raman spectroscopy for analysis of blood gases and analytes |
US9189998B2 (en) | 2012-02-24 | 2015-11-17 | Lg Display Co., Ltd. | Backlight dimming method and liquid crystal display using the same |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1909882B2 (en) | 1969-02-27 | 1976-11-11 | Arnold, Karl M., Dr., 8000 München; Beck, Harald, Prof., 6078 Neu-Isenburg | Photoelectric reflection measurement of pulsing tissue - uses miniature solid state components set in synthetic resin on glass plate |
DE2424549A1 (en) | 1973-05-23 | 1974-12-12 | John Michael Prof Thompson | FLUID ANALYZER |
DE2606991A1 (en) | 1976-02-20 | 1977-08-25 | Nils Dr Med Kaiser | DEVICE FOR DETERMINING THE CONTENT OF METABOLIC PRODUCTS IN THE BLOOD |
DE2934190A1 (en) | 1979-08-23 | 1981-03-19 | Müller, Gerhard, Prof. Dr.-Ing., 7080 Aalen | METHOD AND DEVICE FOR MOLECULAR SPECTROSCOPY, ESPECIALLY FOR DETERMINING METABOLISM PRODUCTS |
US4655225A (en) | 1985-04-18 | 1987-04-07 | Kurabo Industries Ltd. | Spectrophotometric method and apparatus for the non-invasive |
US4890619A (en) * | 1986-04-15 | 1990-01-02 | Hatschek Rudolf A | System for the measurement of the content of a gas in blood, in particular the oxygen saturation of blood |
WO1988006726A1 (en) | 1987-02-25 | 1988-09-07 | Scientific Generics Limited | In vivo blood testing |
US5086229A (en) | 1989-01-19 | 1992-02-04 | Futrex, Inc. | Non-invasive measurement of blood glucose |
US5183042A (en) | 1989-05-23 | 1993-02-02 | Vivascan Corporation | Electromagnetic method and apparatus to measure constituents of human or animal tissue |
US4975581A (en) | 1989-06-21 | 1990-12-04 | University Of New Mexico | Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids |
US5159929A (en) | 1990-06-14 | 1992-11-03 | Morris G Ronald | Insulated rf shield |
US5243983A (en) | 1990-12-14 | 1993-09-14 | Georgia Tech Research Corporation | Non-invasive blood glucose measurement system and method using stimulated raman spectroscopy |
US5261410A (en) | 1991-02-07 | 1993-11-16 | Alfano Robert R | Method for determining if a tissue is a malignant tumor tissue, a benign tumor tissue, or a normal or benign tissue using Raman spectroscopy |
US6690966B1 (en) | 1991-02-26 | 2004-02-10 | Massachusetts Institute Of Technology | Methods of molecular spectroscopy to provide for the diagnosis of tissue |
US5194913A (en) | 1991-03-20 | 1993-03-16 | The United States Of America As Represented By The United States Department Of Energy | Fiber-optic apparatus and method for measurement of luminescence and raman scattering |
US5203328A (en) | 1991-07-17 | 1993-04-20 | Georgia Tech Research Corporation | Apparatus and methods for quantitatively measuring molecular changes in the ocular lens |
US5370114A (en) | 1992-03-12 | 1994-12-06 | Wong; Jacob Y. | Non-invasive blood chemistry measurement by stimulated infrared relaxation emission |
JPH0749309A (en) | 1993-08-05 | 1995-02-21 | Kyoto Daiichi Kagaku:Kk | Light scattering type component concentration measuring apparatus and method |
WO1997036540A1 (en) | 1993-11-30 | 1997-10-09 | Florida Institute Of Technology | Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator |
US5553617A (en) | 1995-01-20 | 1996-09-10 | Hughes Aircraft Company | Noninvasive method and apparatus for determining body chemistry |
US5827181A (en) * | 1995-09-07 | 1998-10-27 | Hewlett-Packard Co. | Noninvasive blood chemistry measurement method and system |
DE19538372A1 (en) | 1995-10-14 | 1997-04-17 | Laser & Med Tech Gmbh | Non-invasive glucose measurement |
JP3592416B2 (en) | 1995-10-31 | 2004-11-24 | 晃敏 吉田 | Measuring device for intraocular substances |
US6232609B1 (en) | 1995-12-01 | 2001-05-15 | Cedars-Sinai Medical Center | Glucose monitoring apparatus and method using laser-induced emission spectroscopy |
AU3721997A (en) | 1996-07-19 | 1998-02-10 | Alexander K. Mills | Device for noninvasive determination of blood parameters |
-
1999
- 1999-07-07 AT AT99933705T patent/ATE225142T1/en not_active IP Right Cessation
- 1999-07-07 CA CA002333565A patent/CA2333565C/en not_active Expired - Fee Related
- 1999-07-07 AU AU49704/99A patent/AU4970499A/en not_active Abandoned
- 1999-07-07 WO PCT/US1999/015217 patent/WO2000001295A1/en active IP Right Grant
- 1999-07-07 DE DE69903306T patent/DE69903306T2/en not_active Expired - Lifetime
- 1999-07-07 ES ES99933705T patent/ES2185374T3/en not_active Expired - Lifetime
- 1999-07-07 JP JP2000557746A patent/JP4486253B2/en not_active Expired - Fee Related
- 1999-07-07 US US09/349,061 patent/US6289230B1/en not_active Expired - Lifetime
- 1999-07-07 EP EP99933705A patent/EP1094746B1/en not_active Expired - Lifetime
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5510894A (en) | 1988-12-22 | 1996-04-23 | Renishaw Plc | Spectroscopic apparatus and methods |
US5372135A (en) * | 1991-12-31 | 1994-12-13 | Vivascan Corporation | Blood constituent determination based on differential spectral analysis |
US5551422A (en) | 1992-11-09 | 1996-09-03 | Boehringer Mannheim Gmbh | Method and apparatus for analytical determination of glucose in a biological matrix |
EP0623308A1 (en) * | 1993-05-07 | 1994-11-09 | Diasense, Inc. | Method for non-invasive measurement of concentration of constituents in blood |
US5553616A (en) | 1993-11-30 | 1996-09-10 | Florida Institute Of Technology | Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator |
DE19518511A1 (en) * | 1994-05-20 | 1995-11-23 | Hermann Dipl Ing Kuenst | Non-invasive, transcutaneous measurement of substances in blood |
US5615673A (en) | 1995-03-27 | 1997-04-01 | Massachusetts Institute Of Technology | Apparatus and methods of raman spectroscopy for analysis of blood gases and analytes |
WO1996039926A1 (en) * | 1995-06-07 | 1996-12-19 | Masimo Corporation | Active pulse blood constituent monitoring |
US9189998B2 (en) | 2012-02-24 | 2015-11-17 | Lg Display Co., Ltd. | Backlight dimming method and liquid crystal display using the same |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001010294A1 (en) * | 1999-08-10 | 2001-02-15 | Gesellschaft zur Förderung der Spektrochemie und angewandten Spektroskopie e.V. | Method and device for measuring blood fractions and clinical parameters in a non-invasive manner |
WO2002003857A2 (en) * | 2000-07-11 | 2002-01-17 | Lightouch Medical, Inc. | Method of tissue modulation for noninvasive measurement of an analyte |
WO2002003857A3 (en) * | 2000-07-11 | 2002-05-23 | Lightouch Medical Inc | Method of tissue modulation for noninvasive measurement of an analyte |
US6711426B2 (en) | 2002-04-09 | 2004-03-23 | Spectros Corporation | Spectroscopy illuminator with improved delivery efficiency for high optical density and reduced thermal load |
US7062306B2 (en) | 2002-04-09 | 2006-06-13 | Spectros Corporation | Spectroscopy illuminator with improved delivery efficiency for high optical density and reduced thermal load |
WO2006002452A1 (en) * | 2004-07-05 | 2006-01-12 | Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung | Raman spectroscopic device and method |
US7813778B2 (en) | 2005-07-29 | 2010-10-12 | Spectros Corporation | Implantable tissue ischemia sensor |
WO2007128533A3 (en) * | 2006-05-05 | 2008-02-14 | Mevitec Gmbh | Device and method for examining and evaluating a biologically active and/or activatable substance |
WO2007128533A2 (en) * | 2006-05-05 | 2007-11-15 | Mevitec Gmbh | Device and method for examining and evaluating a biologically active and/or activatable substance |
EP1890133B1 (en) * | 2006-08-16 | 2016-10-12 | F. Hoffmann-La Roche AG | Method for analysing the sample of a liquid |
WO2009021178A1 (en) * | 2007-08-08 | 2009-02-12 | Chemimage Corporation | Raman difference spectra based disease classification |
US8013991B2 (en) | 2007-08-08 | 2011-09-06 | Chemimage Corporation | Raman difference spectra based disease classification |
EP3641634A4 (en) * | 2017-06-20 | 2021-03-10 | I.R Med Ltd | System and method for noninvasive analysis of subcutaneous tissue |
US11020027B2 (en) | 2017-09-18 | 2021-06-01 | Samsung Electronics Co., Ltd. | Apparatus and method for estimating glucose exposure and generating glucose exposure estimation model |
US11642050B2 (en) | 2017-09-18 | 2023-05-09 | Samsung Electronics Co., Ltd. | Apparatus and method for estimating glucose exposure and generating glucose exposure estimation model |
Also Published As
Publication number | Publication date |
---|---|
US6289230B1 (en) | 2001-09-11 |
AU4970499A (en) | 2000-01-24 |
CA2333565C (en) | 2009-01-27 |
EP1094746A1 (en) | 2001-05-02 |
DE69903306D1 (en) | 2002-11-07 |
DE69903306T2 (en) | 2003-05-22 |
ATE225142T1 (en) | 2002-10-15 |
CA2333565A1 (en) | 2000-01-13 |
EP1094746B1 (en) | 2002-10-02 |
JP2002519130A (en) | 2002-07-02 |
ES2185374T3 (en) | 2003-04-16 |
JP4486253B2 (en) | 2010-06-23 |
WO2000001295A8 (en) | 2000-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6289230B1 (en) | Tissue modulation process for quantitative noninvasive in vivo spectroscopic analysis of tissues | |
US6377828B1 (en) | Method for non-invasive measurement of an analyte | |
CA2373860C (en) | Method and apparatus for non-invasive blood analyte measurement | |
US6353226B1 (en) | Non-invasive sensor capable of determining optical parameters in a sample having multiple layers | |
US6615061B1 (en) | Optical sensor having a selectable sampling distance for determination of analytes | |
US20080255433A1 (en) | Optoacoustic monitoring of multiple parameters | |
US20050043597A1 (en) | Optical vivo probe of analyte concentration within the sterile matrix under the human nail | |
Wróbel | Non-invasive blood glucose monitoring with Raman spectroscopy: prospects for device miniaturization | |
JP2002537931A (en) | Method for measuring analyte concentration using periodic temperature control and phase detection | |
WO2019170716A1 (en) | Sensor for tissue measurements | |
Chaiken et al. | Analyzing near-infrared scattering from human skin to monitor changes in hematocrit | |
US8538499B2 (en) | Process and apparatus for non-invasive, continuous in vivo measurement of hematocrit | |
Välisuo | Optical methods for assessing skin flap survival | |
JP4272024B2 (en) | Optical biological measurement device | |
Attia et al. | Photoacoustic Imaging and Sensing for Biomedical Applications | |
Leahy et al. | Optical instrumentation for the measurement of blood perfusion, concentration, and oxygenation in living microcirculation | |
Ciurczak | Biomedical applications of near-infrared spectroscopy | |
AARON et al. | Engineering and Clinical Aspects of Photoplethysmography | |
Rajkamal et al. | Measurement of Blood Glucose Using the Behavior of Fluorescence in Human Epidermis | |
Stewart | Novel Multifunctional Laser Diagnostics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page |
Free format text: PUBLISHED ABSTRACT REPLACED BY CORRECT ABSTRACT |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2333565 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 557746 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999933705 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999933705 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999933705 Country of ref document: EP |